Using QPOP to Predict Treatment for Sarcomas and Melanomas
Recruiting · NCT04986748 · Observational (researchers observe without assigning treatment) · Lead sponsor: National Cancer Centre, Singapore
View the official record on ClinicalTrials.gov →What this trial is about
This is a multi-cohort proof of concept study involving patients with sarcomas or melanomas. Patient models, both two- and three-dimensional, will be derived from tumour samples. These will then be used to evaluate drug sensitivities ex vivo. Enrolled patients will undergo resections or biopsies as part of standard-of-care, which will be used to generate patient models. Patients will receive standard-of-care systemic treatment. Patient models will also be subjected up to a 14-drug screening panel. The majority of drugs in the respective drug panels has been shown to have activity in the respective cancers and would be used in the standard-of-care setting by treating physicians.
Who can take part
Inclusion criteria
- Diagnosis of sarcoma or melanoma
- At least 1 tumour lesion amenable to fresh biopsy or resection
- Signed informed consent from patient or legal representative
- Able to comply with study-related procedures
Exclusion criteria
- There are no specific exclusion criteria if patients meet the inclusion criteria
Where it is running
1 location listed.
- National Cancer Centre Singapore - Singapore, Singapore